Information Provided By: 
Fly News Breaks for April 13, 2015
MDCO
Apr 13, 2015 | 11:13 EDT
Leerink noted that the FDA just released briefing documents for an advisory committee scheduled for this Wednesday to discuss The Medicines Co.'s response to the Complete Response Letter for Kangreal. Leerink views the documents as a validation of management's recent positive commentary and reiterates Outperform rating and $35 price target on the stock, which is up 3.5% to $29.38 in morning trading.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
